The article by Beninger and Ibara (2016) advocates for improvement in pharmacovigilance with the integration of biomedical informatics advancements. The research practice had evolved since 1961 when the thalidomide strategy was adopted. In addition, the collaborative efforts seen between individuals and organizations have supported the establishment of the agendas. The analysis of the study makes it possible to assess the measures taken to enhance the role of biomedical informatics in healthcare.
Beninger and Ibara (2016) define pharmacovigilance as the science and associated activities in the assessment, recognition, comprehension, and avoidance of adverse effects relating to drugs. The review aims to establish a new perspective of the concept, particularly from the lens of biomedical informatics. Luo et al. (2017) note that there have been numerous vital developments in this field. However, studying the basis for the growth of knowledge in this discipline may be of good use to the medical community.
The research in question illuminates the implications pharmacovigilance has on biomedical informatics. According to Beninger and Ibara (2016), the field has contributed to significant infrastructural advancement since its inception. However, as Hauben et al. (2018) note, the critical systematic assessment of the influence of biomedical informatics on promoting pharmacovigilance remains unexplored. Rapid developments pose a challenge in integrating technology to enhance the safety of information transmitted across different platforms. Therefore, the authors advocate for the rethinking of the integration of technology (Beninger & Ibara, 2016). The main purpose of this solution is to maximize gains in pharmacovigilance.
Biomedical informatics has been pivotal in advancing infrastructural gains in pharmacovigilance. Although the pace is accelerating with time, the anticipated integration of concepts between the two areas remains low. Beninger and Ibara (2016) suggest that those in the field should recognize the changes and take necessary measures to leap maximum merits. Additionally, since the information comes from diverse sources, professionals should adopt structures for consolidating the improvements.
References
Beninger, P., & Ibara, M. A. (2016). Pharmacovigilance and biomedical informatics: A model for future development. Clinical Therapeutics, 38(12), 1-12. Web.
Hauben, M., Reynolds, R., & Caubel, P. (2018). Deconstructing the pharmacovigilance hype cycle. Clinical Therapeutics, 40(12), 1981-1990. Web.
Luo, Y., Thompson, W. K., Herr, T. M., Zeng, Z., Berendsen, M. A., Jonnalagadda, S. R., Carson, M. B., & Starren, J. (2017). Natural language processing for EHR-based pharmacovigilance: A structured review. Drug Safety, 40(11), 1075-1089. Web.